Our purpose

Supporting life-changing therapies through long-term strategic partnerships

Our DNA

Decades of experience backing innovation

”la Caixa” Foundation
120+

years of commitment with society and healthcare

We have a strong legacy to the values of ”la Caixa” Foundation, one of the largest foundations of the world, with 120+ years of history and a commitment with society and healthcare.

CriteriaCaixa
50+

billions of euros under management

We are the evergreen Life Sciences venture capital arm of CriteriaCaixa, the holding that manages the wealth of ”la Caixa” Foundation.

Criteria Capital Risc
20+

years of VC experience 

Criteria Bio Ventures is the new specialized vehicle of Criteria Capital Risc (the venture capital arm of CriteriaCaixa) fully dedicated to investments in the Life Sciences. As such, we stand on 20+ years of venture capital experience of CCR, one of the first VC funds in Spain to invest in this sector.

CaixaImpulse
50+

spin-offs since 2015

In parallel with our investment activity, we promote the CaixaImpulse programme to facilitate technology transfer and the development of early-stage companies. The programme, managed by the ”la Caixa” Foundation with our support, has provided funding to more than 200 projects led by research institutions in Spain and Portugal. In particular, 40 of these projects have been successfully established as spin-offs.

Our investment thesis

We are a Life Sciences venture fund backing private biotech companies in Europe and North America, with special focus in Spain and Portugal.

We team up with driven entrepreneurs and fellow investors who aim to revolutionize healthcare through disruptive and well-protected innovations that have the potential to transform patients’ lives where there is a significant unmet medical need.

We invest agnostically across modalities and disease areas, offering evergreen support until achieving meaningful impact.

Founders spotligh

Disruptive companies improving patients’ lives

Our manifesto
News

Our founders’ insights and achievements

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

08 Jan 2026: AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

08 Jan 2026: NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s